New combo therapy aims to tame melanoma treatment side effects

NCT ID NCT05428007

First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 25 times

Summary

This study tests whether adding the drug sarilumab to a standard immunotherapy combination can reduce severe side effects and work better for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive sarilumab along with ipilimumab, nivolumab, and relatlimab. The goal is to see if this approach is safer and more effective than current treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02215, United States

    Contact

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

    Contact

  • NYU Langone Health

    RECRUITING

    New York, New York, 10016, United States

    Contact Phone: •••-•••-••••

    Contact

  • The Angeles Clinic at Cedars Sinai

    RECRUITING

    Los Angeles, California, 90025, United States

    Contact

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.